Barclays Raises Revvity (NYSE:RVTY) Price Target to $125.00

Revvity (NYSE:RVTY) had its price target lifted by Barclays from $115.00 to $125.00 in a research note released on Tuesday, Benzinga reports. They currently have an equal weight rating on the stock.

Several other research firms have also commented on RVTY. SVB Leerink started coverage on shares of Revvity in a report on Monday, July 8th. They issued an outperform rating and a $125.00 price target on the stock. TD Cowen upped their target price on Revvity from $123.00 to $130.00 and gave the stock a buy rating in a research note on Tuesday, April 30th. Jefferies Financial Group lifted their price target on Revvity from $115.00 to $125.00 and gave the company a hold rating in a research report on Monday. Leerink Partnrs upgraded Revvity to a strong-buy rating in a research report on Monday, July 8th. Finally, Robert W. Baird lifted their target price on shares of Revvity from $126.00 to $127.00 and gave the company an outperform rating in a report on Tuesday, April 30th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Revvity has a consensus rating of Moderate Buy and a consensus target price of $123.81.

Revvity Trading Down 0.5 %

Shares of NYSE:RVTY opened at $125.02 on Tuesday. The company has a quick ratio of 1.92, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Revvity has a 52-week low of $79.50 and a 52-week high of $128.15. The stock has a market cap of $15.43 billion, a price-to-earnings ratio of 103.32, a PEG ratio of 2.98 and a beta of 1.05. The business has a 50-day moving average price of $109.89 and a 200-day moving average price of $106.94.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, July 29th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. The company had revenue of $691.70 million during the quarter, compared to analyst estimates of $690.33 million. Revvity had a net margin of 6.26% and a return on equity of 7.34%. Revvity’s revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period last year, the firm posted $1.21 EPS. Equities analysts predict that Revvity will post 4.75 EPS for the current year.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.22%. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Insiders Place Their Bets

In other news, insider Joel S. Goldberg sold 4,000 shares of Revvity stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $110.46, for a total value of $441,840.00. Following the sale, the insider now directly owns 36,900 shares of the company’s stock, valued at $4,075,974. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVTY. Rhumbline Advisers grew its stake in Revvity by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 211,814 shares of the company’s stock valued at $22,211,000 after acquiring an additional 754 shares in the last quarter. Natixis Advisors LLC acquired a new stake in shares of Revvity in the second quarter valued at approximately $1,111,000. Triodos Investment Management BV boosted its stake in Revvity by 7.6% during the second quarter. Triodos Investment Management BV now owns 15,600 shares of the company’s stock worth $1,636,000 after buying an additional 1,100 shares during the last quarter. nVerses Capital LLC purchased a new stake in Revvity in the 2nd quarter valued at $73,000. Finally, Rothschild Investment LLC acquired a new stake in shares of Revvity in the 2nd quarter worth $25,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.